Community Acquired Pneumonia (CAP) Market Research Report: Market size, Industry outlook, Market Forecast, Demand Analysis,Market Share, Market Report 2018-2023
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Community Acquired Pneumonia (CAP) Market
Community Acquired Pneumonia (CAP) Market: By Testing & Diagnosis (Chest X-ray/radiography, Sputum Gram stain and/or culture, Blood Cultures), By Therapies & Drugs, By Patient Age group & By Geography - Forecast(2018 - 2023)
Report Code : HCR 0128
Updated Date: 21 January, 2018  

  • Report Description
  • Table of Contents
  • Tables And Figures
  • Customization Options
1. Community Acquired Pneumonia (CAP) Market Overview 
2. Executive Summary  
3. Community Acquired Pneumonia (CAP) Market Landscape 
   3.1. Market Share Analysis 
   3.2. Comparative Analysis 
      3.2.1. End-User Profiling 
      3.2.2. Financial Analysis of Top 5 Players 
4. Community Acquired Pneumonia (CAP) Market Forces 
   4.1. Market Drivers 
   4.2. Market Constraints 
   4.3. Market Challenges  
   4.4. Attractiveness of Industry  
      4.4.1. Power of Supplier 
      4.4.2. Power of Consumer 
      4.4.3. Threat of New Entrants 
      4.4.4. Threat of Substitution 
      4.4.5. Degree of Competition 
5. Community Acquired Pneumonia (CAP) Market Strategic Analysis 
   5.1. Value Chain Analysis 
   5.2. Pricing Analysis  
   5.3. Opportunity Analysis 
   5.4. Product Life Cycle Analysis  
   5.5. Suppliers & Distributors 
6. Community Acquired Pneumonia (CAP) Market- By Testing & Diagnosis 
   6.1. Chest X-ray/radiography 
   6.2. Sputum Gram stain and/or culture 
   6.3. Blood Cultures 
   6.4. Others 
      6.4.1. COMPLETE BLOOD CELL (CBC) COUNT  
      6.4.2. SERUM SODIUM LEVEL 
      6.4.3. SERUM BLOOD UREA NITROGEN (BUN) AND CREATININE LEVELS 
      6.4.4. SERUM TRANSAMINASE LEVELS 
      6.4.5. SERUM PHOSPHORUS LEVEL 
      6.4.6. LACTIC ACID LEVEL 
      6.4.7. CREATINE PHOSPHOKINASE (CPK) 
      6.4.8. C-REACTIVE PROTEIN (CRP) 
      6.4.9. LACTATE DEHYDROGENASE (LDH) 
      6.4.10. PROCALCITONIN 
      6.4.11. COLD AGGLUTININ TITERS 
      6.4.12. URINARY ANTIGEN TESTING  
      6.4.13. SEROLOGIC STUDIES FOR M PNEUMONIAE 
      6.4.14. POLYMERASE CHAIN REACTION (PCR) TESTING 
7. Community Acquired Pneumonia (CAP) Market- By Therapies & Drugs 
   7.1. Antiviral Threapy 
      7.1.1. RIBAVIRIN 
      7.1.2. OSELTAMIVIR 
      7.1.3. ZANAMIVIR 
      7.1.4. ACYCLOVIR 
   7.2. Antibiotic Threapy 
      7.1.1. AMOXICILLIN 
      7.1.2. AZITHROMYCIN OR CLARITHROMYCIN 
      7.1.3. AMPICILLIN 
      7.1.4. VANCOMYCIN OR CLINDAMYCIN 
      7.1.5. CEFTRIAXONE OR CEFOTAXIME 
      7.1.6. GENTAMICIN 
8. Community Acquired Pneumonia (CAP) Market- By Drugs provided to different age groups 
   8.1. Newborns 
      8.1.1. AMPICILLIN 
      8.1.2. GENTAMICIN 
   8.2. Children 
      8.2.1. AMOXICILLIN 
      8.2.2. CEFPODOXIME 
      8.2.3. AMPICILLIN 
      8.2.4. CEFTRIAXONE OR CEFOTAXIME 
   8.3. Adults 
      8.3.1. AZITHROMYCIN OR CLARITHROMYCIN 
      8.3.2. CEFPODOXIME 
      8.3.3. AMOXICILLIN 
      8.3.4. CEFTRIAXONE OR CEFOTAXIME 
9. Community Acquired Pneumonia (CAP) Market- By Geography 
   9.1. North America 
      9.1.1. The U.S. 
      9.1.2. Canada 
      9.1.3. Rest of North America 
   9.2. Europe 
      9.2.1. The U.K. 
      9.2.2. Germany 
      9.2.3. France 
      9.2.4. Italy 
      9.2.5. Rest of Europe 
   9.3. Asia-Pacific 
      9.3.1. China 
      9.3.2. India 
      9.3.3. Japan 
      9.3.4. Rest of APAC 
   9.4. Latin America 
      9.4.1. Brazil
      9.4.2. Argentina 
      9.4.3. Mexico 
      9.4.4. Rest of Latin America 
   9.5. Rest of the World 
      9.5.1. The Middle East 
      9.5.2. Africa 
10. Community Acquired Pneumonia (CAP) Market Entropy 
   10.1. New Product Launches 
   10.2. M&As, Collaborations, Partnerships & JVs 
11. Company Profiles (Overview, Financials, Products & Services, Recent Developments, Competitors & Customers) 
   11.1. Pfizer 
   11.2. Astrazeneca Plc. 
   11.3. Bioaegis Therapeutics, Inc. 
   11.4. Biotest AG 
   11.5. C10 Pharma AS 
   11.6. Kyorin Pharmaceutical Co., Ltd 
   11.7. Melinta Therapeutics, Inc 
   11.8. Merck & Co., Inc. 
   11.9. NABRIVA THERAPEUTICS AG 
   11.10. Paratek Pharmaceuticals, Inc 
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
12. Appendix 
   12.1. Abbreviations 
   12.2. Sources 
   12.3. Research Methodology 
   12.4. Bibliography 
   12.5. Compilation of Expert Insights 
Community Acquired Pneumonia (CAP) is an infectious disease that affects lungs due to bacterial or viral attack. It is most commonly seen in individuals with less contact with healthcare /medical systems or organizations. CAP is one of the major causes of high mortality. Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis are the typical type of bacterial pathogens that causes CAP. This disease is associated with filling of fluids in alveoli of lungs which inhibits the lung functioning, fever, chest pain, and cough. Besides, the major symptoms include mental confusion, prominent headaches, myalgias, ear pain, abdominal pain, diarrhea, rashes, nonexudative pharyngitis, hemoptysis, splenomegaly, and relative bradycardia. CAP affects all age groups from infants to old age.

The report highlights various diagnosis and testing methods used to detect CAP. Physical examination by experts may sometimes reveal the signs associated with CAP which further can be detected and confirmed by several diagnostic tests.The major diagnostic tests are chest x-ray or radiography, Sputum Gram stain and/or culture, and blood cultures. Besides there are several pathology test to detect CAP depending on the severity of illness ; these includes Complete blood cell (CBC) count with differential, Serum sodium level, Serum blood urea nitrogen (BUN) and creatinine levels, Serum transaminase levels, Serum phosphorus level, Lactic acid level, Creatine phosphokinase (CPK), C-reactive protein (CRP), Lactate dehydrogenase (LDH), Procalcitonin, Cold agglutinin titers, Urinary antigen testing for Legionella species and S pneumonia, Serologic studies for M pneumoniae, C pneumoniae, Bordetella pertussis, C burnetii, and Molecular diagnostics/polymerase chain reaction (PCR) testing. 

Community Acquired Pneumonia (CAP) Market

The key industry factors affecting the revenue generation in the CAP testing and diagnosis market are analyzed and included in the report. Moreover, the major market dynamic factors such as drivers, restraints, challenges and opportunities and their impact on the industry in next 5 years are weighted and captured exhaustively in the report. The report tracks the entire value chain of the market along with the suppliers and distributor analysis. Furthermore, the industry attractiveness section in the report offers the significance of the competitive rivalry in the market affected by the forces such as power of supplier, power of buyer, threat of new entrant and threat of substitution. The report provides precise and comprehensive insights on the market trends, industry trends, and macro & micro factors impacting the market growth.

In depth analysis of treatment and therapies used to cure CAP accounts for major portion in the report. The treatments and drugs vary depending on the age group of affected individual. Majorly antibacterial and antiviral drugs are prescribed to the patients after the detection of CAP. The common antiviral drugs include ribavirin, oseltamivir , zanamivir, and acyclovir; whereas, amoxicillin, azithromycin or clarithromycin, ampicillin, vancomycin or clindamycin , ceftriaxone or cefotaxime, and gentamicin are the major antibiotics prescribed to CAP affected patients. The report also analyzes the penetration of these therapies across all major geographies.

The market of CAP treatment and diagnosis in further segmented with respect to major geographies of North America, Europe, Asia-Pacific, and Latin America. Moreover, the countries generating high revenue in these regions have also been analyzed along with exhaustive coverage of developments and innovation in these countries. The report also offers extensive research on the key players in this market and detailed insights on the competitiveness of these players.The key business strategies such as mergers & acquisitions, partnerships, collaborations, and contracts adopted by the major players are also identifies and analyzed in the report. 

The major players profiled in the report include:
  • AstraZeneca Plc
  • BioAegis Therapeutics, Inc 
  • Biotest AG 
  • Kyorin Pharmaceutical Co., Ltd 
  • Pfizer
List of Tables

Table 1: Community Acquired Pneumonia (CAP) Market Overview 2017-2023
Table 2: Community Acquired Pneumonia (CAP) Market Leader Analysis 2017-2018 (US$)
Table 3: Community Acquired Pneumonia (CAP) Market Product Analysis 2017-2018 (US$)
Table 4: Community Acquired Pneumonia (CAP) Market End User Analysis 2017-2018 (US$)
Table 5: Community Acquired Pneumonia (CAP) Market Patent Analysis 2013-2018* (US$)
Table 6: Community Acquired Pneumonia (CAP) Market Financial Analysis 2017-2018 (US$)
Table 7: Community Acquired Pneumonia (CAP) Market Driver Analysis 2017-2018 (US$)
Table 8: Community Acquired Pneumonia (CAP) Market Challenges Analysis 2017-2018 (US$)
Table 9: Community Acquired Pneumonia (CAP) Market Constraint Analysis 2017-2018 (US$)
Table 10: Community Acquired Pneumonia (CAP) Market Supplier Bargaining Power Analysis 2017-2018 (US$)
Table 11: Community Acquired Pneumonia (CAP) Market Buyer Bargaining Power Analysis 2017-2018 (US$)
Table 12: Community Acquired Pneumonia (CAP) Market Threat of Substitutes Analysis 2017-2018 (US$)
Table 13: Community Acquired Pneumonia (CAP) Market Threat of New Entrants Analysis 2017-2018 (US$)
Table 14: Community Acquired Pneumonia (CAP) Market Degree of Competition Analysis 2017-2018 (US$)
Table 15: Community Acquired Pneumonia (CAP) Market Value Chain Analysis 2017-2018 (US$)
Table 16: Community Acquired Pneumonia (CAP) Market Pricing Analysis 2018-2023 (US$)
Table 17: Community Acquired Pneumonia (CAP) Market Opportunities Analysis 2018-2023 (US$)
Table 18: Community Acquired Pneumonia (CAP) Market Product Life Cycle Analysis 2018-2023 (US$)
Table 19: Community Acquired Pneumonia (CAP) Market Supplier Analysis 2017-2018 (US$)
Table 20: Community Acquired Pneumonia (CAP) Market Distributor Analysis 2017-2018 (US$)
Table 21: Community Acquired Pneumonia (CAP) Market Trend Analysis 2017-2018 (US$)
Table 22: Community Acquired Pneumonia (CAP) Market Size 2017 (US$)
Table 23: Community Acquired Pneumonia (CAP) Market Forecast Analysis 2018-2023 (US$)
Table 24: Community Acquired Pneumonia (CAP) Market Sales Forecast Analysis 2018-2023 (Units)
Table 25: Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Testing & Diagnosis, 2018-2023 ($)
Table 26: Community Acquired Pneumonia (CAP) Market By Testing & Diagnosis, Revenue & Volume, By Chest X-ray/radiography, 2018-2023 ($)
Table 27: Community Acquired Pneumonia (CAP) Market By Testing & Diagnosis, Revenue & Volume, By Sputum Gram stain and/or culture, 2018-2023 ($)
Table 28: Community Acquired Pneumonia (CAP) Market By Testing & Diagnosis, Revenue & Volume, By Blood Cultures, 2018-2023 ($)
Table 29: Community Acquired Pneumonia (CAP) Market By Testing & Diagnosis, Revenue & Volume, By COMPLETE BLOOD CELL (CBC) COUNT, 2018-2023 ($)
Table 30: Community Acquired Pneumonia (CAP) Market By Testing & Diagnosis, Revenue & Volume, By SERUM SODIUM LEVEL, 2018-2023 ($)
Table 31: Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Therapies & Drugs, 2018-2023 ($)
Table 32: Community Acquired Pneumonia (CAP) Market By Therapies & Drugs, Revenue & Volume, By Antiviral Threapy, 2018-2023 ($)
Table 33: Community Acquired Pneumonia (CAP) Market By Therapies & Drugs, Revenue & Volume, By Antibiotic Threapy, 2018-2023 ($)
Table 34: Community Acquired Pneumonia (CAP) Market By Drugs provided to different age groups, Revenue & Volume, By Newborns, 2018-2023 ($)
Table 35: Community Acquired Pneumonia (CAP) Market By Drugs provided to different age groups, Revenue & Volume, By Children, 2018-2023 ($)
Table 36: Community Acquired Pneumonia (CAP) Market By Drugs provided to different age groups, Revenue & Volume, By Adults, 2018-2023 ($)
Table 37: North America Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Testing & Diagnosis, 2018-2023 ($)
Table 38: North America Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Therapies & Drugs, 2018-2023 ($)
Table 39: North America Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Drugs provided to different age groups, 2018-2023 ($)
Table 40: South america Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Testing & Diagnosis, 2018-2023 ($)
Table 41: South america Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Therapies & Drugs, 2018-2023 ($)
Table 42: South america Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Drugs provided to different age groups, 2018-2023 ($)
Table 43: Europe Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Testing & Diagnosis, 2018-2023 ($)
Table 44: Europe Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Therapies & Drugs, 2018-2023 ($)
Table 45: Europe Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Drugs provided to different age groups, 2018-2023 ($)
Table 46: APAC Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Testing & Diagnosis, 2018-2023 ($)
Table 47: APAC Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Therapies & Drugs, 2018-2023 ($)
Table 48: APAC Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Drugs provided to different age groups, 2018-2023 ($)
Table 49: Middle East & Africa Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Testing & Diagnosis, 2018-2023 ($)
Table 50: Middle East & Africa Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Therapies & Drugs, 2018-2023 ($)
Table 51: Middle East & Africa Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Drugs provided to different age groups, 2018-2023 ($)
Table 52: Russia Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Testing & Diagnosis, 2018-2023 ($)
Table 53: Russia Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Therapies & Drugs, 2018-2023 ($)
Table 54: Russia Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Drugs provided to different age groups, 2018-2023 ($)
Table 55: Israel Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Testing & Diagnosis, 2018-2023 ($)
Table 56: Israel Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Therapies & Drugs, 2018-2023 ($)
Table 57: Israel Community Acquired Pneumonia (CAP) Market, Revenue & Volume, By Drugs provided to different age groups, 2018-2023 ($)
Table 58: Top Companies 2017 (US$)Community Acquired Pneumonia (CAP) Market, Revenue & Volume
Table 59: Product Launch 2017-2018Community Acquired Pneumonia (CAP) Market, Revenue & Volume
Table 60: Mergers & Acquistions 2017-2018Community Acquired Pneumonia (CAP) Market, Revenue & Volume


List of Figures

Figure 1: Overview of Community Acquired Pneumonia (CAP) Market 2017-2023
Figure 2: Market Share Analysis for Community Acquired Pneumonia (CAP) Market 2017 (US$)
Figure 3: Product Comparison in Community Acquired Pneumonia (CAP) Market 2017-2018 (US$)
Figure 4: End User Profile for Community Acquired Pneumonia (CAP) Market 2017-2018 (US$)
Figure 5: Patent Application and Grant in Community Acquired Pneumonia (CAP) Market 2013-2018* (US$)
Figure 6: Top 5 Companies Financial Analysis in Community Acquired Pneumonia (CAP) Market 2017-2018 (US$)
Figure 7: Market Entry Strategy in Community Acquired Pneumonia (CAP) Market 2017-2018
Figure 8: Ecosystem Analysis in Community Acquired Pneumonia (CAP) Market 2017
Figure 9: Average Selling Price in Community Acquired Pneumonia (CAP) Market 2017-2023
Figure 10: Top Opportunites in Community Acquired Pneumonia (CAP) Market 2017-2018
Figure 11: Market Life Cycle Analysis in Community Acquired Pneumonia (CAP) Market Market Life Cycle Analysis in 3D Printing
Figure 12: GlobalBy Testing & DiagnosisCommunity Acquired Pneumonia (CAP) Market Revenue, 2018-2023 ($)
Figure 13: GlobalBy Therapies & Drugs Community Acquired Pneumonia (CAP) Market Revenue, 2018-2023 ($)
Figure 14: GlobalBy Drugs provided to different age groups Community Acquired Pneumonia (CAP) Market Revenue, 2018-2023 ($)
Figure 15: Global Community Acquired Pneumonia (CAP) Market - By Geography
Figure 16: Global Community Acquired Pneumonia (CAP) Market Value & Volume, By Geography, 2018-2023 ($) 
Figure 17: Global Community Acquired Pneumonia (CAP) Market CAGR, By Geography, 2018-2023 (%)
Figure 18: North America Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 19: US Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 20: US GDP and Population, 2017-2018 ($)
Figure 21: US GDP – Composition of 2017, By Sector of Origin
Figure 22: US Export and Import Value & Volume, 2017-2018 ($)
Figure 23: Canada Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 24: Canada GDP and Population, 2017-2018 ($)
Figure 25: Canada GDP – Composition of 2017, By Sector of Origin
Figure 26: Canada Export and Import Value & Volume, 2017-2018 ($)
Figure 27: Mexico Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 28: Mexico GDP and Population, 2017-2018 ($)
Figure 29: Mexico GDP – Composition of 2017, By Sector of Origin
Figure 30: Mexico Export and Import Value & Volume, 2017-2018 ($)
Figure 31: South America Community Acquired Pneumonia (CAP) Market South America 3D Printing Market Value & Volume, 2018-2023 ($)
Figure 32: Brazil Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 33: Brazil GDP and Population, 2017-2018 ($)
Figure 34: Brazil GDP – Composition of 2017, By Sector of Origin
Figure 35: Brazil Export and Import Value & Volume, 2017-2018 ($)
Figure 36: Venezuela Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 37: Venezuela GDP and Population, 2017-2018 ($)
Figure 38: Venezuela GDP – Composition of 2017, By Sector of Origin
Figure 39: Venezuela Export and Import Value & Volume, 2017-2018 ($)
Figure 40: Argentina Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 41: Argentina GDP and Population, 2017-2018 ($)
Figure 42: Argentina GDP – Composition of 2017, By Sector of Origin
Figure 43: Argentina Export and Import Value & Volume, 2017-2018 ($)
Figure 44: Ecuador Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 45: Ecuador GDP and Population, 2017-2018 ($)
Figure 46: Ecuador GDP – Composition of 2017, By Sector of Origin
Figure 47: Ecuador Export and Import Value & Volume, 2017-2018 ($)
Figure 48: Peru Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 49: Peru GDP and Population, 2017-2018 ($)
Figure 50: Peru GDP – Composition of 2017, By Sector of Origin
Figure 51: Peru Export and Import Value & Volume, 2017-2018 ($)
Figure 52: Colombia Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 53: Colombia GDP and Population, 2017-2018 ($)
Figure 54: Colombia GDP – Composition of 2017, By Sector of Origin
Figure 55: Colombia Export and Import Value & Volume, 2017-2018 ($)
Figure 56: Costa Rica Community Acquired Pneumonia (CAP) Market Costa Rica 3D Printing Market Value & Volume, 2018-2023 ($)
Figure 57: Costa Rica GDP and Population, 2017-2018 ($)
Figure 58: Costa Rica GDP – Composition of 2017, By Sector of Origin
Figure 59: Costa Rica Export and Import Value & Volume, 2017-2018 ($)
Figure 60: Europe Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 61: U.K Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 62: U.K GDP and Population, 2017-2018 ($)
Figure 63: U.K GDP – Composition of 2017, By Sector of Origin
Figure 64: U.K Export and Import Value & Volume, 2017-2018 ($)
Figure 65: Germany Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 66: Germany GDP and Population, 2017-2018 ($)
Figure 67: Germany GDP – Composition of 2017, By Sector of Origin
Figure 68: Germany Export and Import Value & Volume, 2017-2018 ($)
Figure 69: Italy Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 70: Italy GDP and Population, 2017-2018 ($)
Figure 71: Italy GDP – Composition of 2017, By Sector of Origin
Figure 72: Italy Export and Import Value & Volume, 2017-2018 ($)
Figure 73: France Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 74: France GDP and Population, 2017-2018 ($)
Figure 75: France GDP – Composition of 2017, By Sector of Origin
Figure 76: France Export and Import Value & Volume, 2017-2018 ($)
Figure 77: Netherlands Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 78: Netherlands GDP and Population, 2017-2018 ($)
Figure 79: Netherlands GDP – Composition of 2017, By Sector of Origin
Figure 80: Netherlands Export and Import Value & Volume, 2017-2018 ($)
Figure 81: Belgium Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 82: Belgium GDP and Population, 2017-2018 ($)
Figure 83: Belgium GDP – Composition of 2017, By Sector of Origin
Figure 84: Belgium Export and Import Value & Volume, 2017-2018 ($)
Figure 85: Spain Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 86: Spain GDP and Population, 2017-2018 ($)
Figure 87: Spain GDP – Composition of 2017, By Sector of Origin
Figure 88: Spain Export and Import Value & Volume, 2017-2018 ($)
Figure 89: Denmark Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 90: Denmark GDP and Population, 2017-2018 ($)
Figure 91: Denmark GDP – Composition of 2017, By Sector of Origin
Figure 92: Denmark Export and Import Value & Volume, 2017-2018 ($)
Figure 93: APAC Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 94: China Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023
Figure 95: China GDP and Population, 2017-2018 ($)
Figure 96: China GDP – Composition of 2017, By Sector of Origin
Figure 97: China Export and Import Value & Volume, 2017-2018 ($)Community Acquired Pneumonia (CAP) Market China Export and Import Value & Volume, 2017-2018 ($)
Figure 98: Australia Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 99: Australia GDP and Population, 2017-2018 ($)
Figure 100: Australia GDP – Composition of 2017, By Sector of Origin
Figure 101: Australia Export and Import Value & Volume, 2017-2018 ($)
Figure 102: South Korea Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 103: South Korea GDP and Population, 2017-2018 ($)
Figure 104: South Korea GDP – Composition of 2017, By Sector of Origin
Figure 105: South Korea Export and Import Value & Volume, 2017-2018 ($)
Figure 106: India Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 107: India GDP and Population, 2017-2018 ($)
Figure 108: India GDP – Composition of 2017, By Sector of Origin
Figure 109: India Export and Import Value & Volume, 2017-2018 ($)
Figure 110: Taiwan Community Acquired Pneumonia (CAP) Market Taiwan 3D Printing Market Value & Volume, 2018-2023 ($)
Figure 111: Taiwan GDP and Population, 2017-2018 ($)
Figure 112: Taiwan GDP – Composition of 2017, By Sector of Origin
Figure 113: Taiwan Export and Import Value & Volume, 2017-2018 ($)
Figure 114: Malaysia Community Acquired Pneumonia (CAP) Market Malaysia 3D Printing Market Value & Volume, 2018-2023 ($)
Figure 115: Malaysia GDP and Population, 2017-2018 ($)
Figure 116: Malaysia GDP – Composition of 2017, By Sector of Origin
Figure 117: Malaysia Export and Import Value & Volume, 2017-2018 ($)
Figure 118: Hong Kong Community Acquired Pneumonia (CAP) Market Hong Kong 3D Printing Market Value & Volume, 2018-2023 ($)
Figure 119: Hong Kong GDP and Population, 2017-2018 ($)
Figure 120: Hong Kong GDP – Composition of 2017, By Sector of Origin
Figure 121: Hong Kong Export and Import Value & Volume, 2017-2018 ($)
Figure 122: Middle East & Africa Community Acquired Pneumonia (CAP) Market Middle East & Africa 3D Printing Market Value & Volume, 2018-2023 ($)
Figure 123: Russia Community Acquired Pneumonia (CAP) Market Russia 3D Printing Market Value & Volume, 2018-2023 ($)
Figure 124: Russia GDP and Population, 2017-2018 ($)
Figure 125: Russia GDP – Composition of 2017, By Sector of Origin
Figure 126: Russia Export and Import Value & Volume, 2017-2018 ($)
Figure 127: Israel Community Acquired Pneumonia (CAP) Market Value & Volume, 2018-2023 ($)
Figure 128: Israel GDP and Population, 2017-2018 ($)
Figure 129: Israel GDP – Composition of 2017, By Sector of Origin
Figure 130: Israel Export and Import Value & Volume, 2017-2018 ($)
Figure 131: Entropy Share, By Strategies, 2017-2018* (%)Community Acquired Pneumonia (CAP) Market
Figure 132: Developments, 2017-2018*Community Acquired Pneumonia (CAP) Market
Figure 133: Company 1 Community Acquired Pneumonia (CAP) Market Net Revenue, By Years, 2017-2018* ($)
Figure 134: Company 1 Community Acquired Pneumonia (CAP) Market Net Revenue Share, By Business segments, 2017 (%)
Figure 135: Company 1 Community Acquired Pneumonia (CAP) Market Net Sales Share, By Geography, 2017 (%)
Figure 136: Company 2 Community Acquired Pneumonia (CAP) Market Net Revenue, By Years, 2017-2018* ($)
Figure 137: Company 2 Community Acquired Pneumonia (CAP) Market Net Revenue Share, By Business segments, 2017 (%)
Figure 138: Company 2 Community Acquired Pneumonia (CAP) Market Net Sales Share, By Geography, 2017 (%)
Figure 139: Company 3 Community Acquired Pneumonia (CAP) Market Net Revenue, By Years, 2017-2018* ($)
Figure 140: Company 3 Community Acquired Pneumonia (CAP) Market Net Revenue Share, By Business segments, 2017 (%)
Figure 141: Company 3 Community Acquired Pneumonia (CAP) Market Net Sales Share, By Geography, 2017 (%)
Figure 142: Company 4 Community Acquired Pneumonia (CAP) Market Net Revenue, By Years, 2017-2018* ($)
Figure 143: Company 4 Community Acquired Pneumonia (CAP) Market Net Revenue Share, By Business segments, 2017 (%)
Figure 144: Company 4 Community Acquired Pneumonia (CAP) Market Net Sales Share, By Geography, 2017 (%)
Figure 145: Company 5 Community Acquired Pneumonia (CAP) Market Net Revenue, By Years, 2017-2018* ($)
Figure 146: Company 5 Community Acquired Pneumonia (CAP) Market Net Revenue Share, By Business segments, 2017 (%)
Figure 147: Company 5 Community Acquired Pneumonia (CAP) Market Net Sales Share, By Geography, 2017 (%)
Figure 148: Company 6 Community Acquired Pneumonia (CAP) Market Net Revenue, By Years, 2017-2018* ($)
Figure 149: Company 6 Community Acquired Pneumonia (CAP) Market Net Revenue Share, By Business segments, 2017 (%)
Figure 150: Company 6 Community Acquired Pneumonia (CAP) Market Net Sales Share, By Geography, 2017 (%)
Figure 151: Company 7 Community Acquired Pneumonia (CAP) Market Net Revenue, By Years, 2017-2018* ($)
Figure 152: Company 7 Community Acquired Pneumonia (CAP) Market Net Revenue Share, By Business segments, 2017 (%)
Figure 153: Company 7 Community Acquired Pneumonia (CAP) Market Net Sales Share, By Geography, 2017 (%)
Figure 154: Company 8 Community Acquired Pneumonia (CAP) Market Net Revenue, By Years, 2017-2018* ($)
Figure 155: Company 8 Community Acquired Pneumonia (CAP) Market Net Revenue Share, By Business segments, 2017 (%)
Figure 156: Company 8 Community Acquired Pneumonia (CAP) Market Net Sales Share, By Geography, 2017 (%)
Figure 157: Company 9 Community Acquired Pneumonia (CAP) Market Net Revenue, By Years, 2017-2018* ($)
Figure 158: Company 9 Community Acquired Pneumonia (CAP) Market Net Revenue Share, By Business segments, 2017 (%)
Figure 159: Company 9 Community Acquired Pneumonia (CAP) Market Net Sales Share, By Geography, 2017 (%)
Figure 160: Company 10 Community Acquired Pneumonia (CAP) Market Net Revenue, By Years, 2017-2018* ($)
Figure 161: Company 10 Community Acquired Pneumonia (CAP) Market Net Revenue Share, By Business segments, 2017 (%)
Figure 162: Company 10 Community Acquired Pneumonia (CAP) Market Net Sales Share, By Geography, 2017 (%)
Figure 163: Company 11 Community Acquired Pneumonia (CAP) Market Net Revenue, By Years, 2017-2018* ($)
Figure 164: Company 11 Community Acquired Pneumonia (CAP) Market Net Revenue Share, By Business segments, 2017 (%)
Figure 165: Company 11 Community Acquired Pneumonia (CAP) Market Net Sales Share, By Geography, 2017 (%)
Figure 166: Company 12 Community Acquired Pneumonia (CAP) Market Net Revenue, By Years, 2017-2018* ($)
Figure 167: Company 12 Community Acquired Pneumonia (CAP) Market Net Revenue Share, By Business segments, 2017 (%)
Figure 168: Company 12 Community Acquired Pneumonia (CAP) Market Net Sales Share, By Geography, 2017 (%)
Figure 169: Company 13 Community Acquired Pneumonia (CAP) Market Net Revenue, By Years, 2017-2018* ($)
Figure 170: Company 13 Community Acquired Pneumonia (CAP) Market Net Revenue Share, By Business segments, 2017 (%)
Figure 171: Company 13 Community Acquired Pneumonia (CAP) Market Net Sales Share, By Geography, 2017 (%)
Figure 172: Company 14 Community Acquired Pneumonia (CAP) Market Net Revenue, By Years, 2017-2018* ($)
Figure 173: Company 14 Community Acquired Pneumonia (CAP) Market Net Revenue Share, By Business segments, 2017 (%)
Figure 174: Company 14 Community Acquired Pneumonia (CAP) Market Net Sales Share, By Geography, 2017 (%)
Figure 175: Company 15 Community Acquired Pneumonia (CAP) Market Net Revenue, By Years, 2017-2018* ($)
Figure 176: Company 15 Community Acquired Pneumonia (CAP) Market Net Revenue Share, By Business segments, 2017 (%)
Figure 177: Company 15 Community Acquired Pneumonia (CAP) Market Net Sales Share, By Geography, 2017 (%)
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll